Table 1: Clinical demographic and laboratory findings of participants according to diabetes mellitus development.
|
Variables |
All population n=93 |
Diabetes mellitus |
p |
|
|
Developed |
Not – Developed |
|||
|
n=17 |
n=76 |
|||
|
Gender, n(%) |
|
|
|
|
|
Female |
65 (69.9) |
10 (58.8) |
55 (72.4) |
0.380 |
|
Male |
28 (30.1) |
7 (41.2) |
21 (27.6) |
|
|
Age (year) |
56.0±11.1 |
58.5±12.8 |
55.4±10.6 |
0.299 |
|
<65 |
73 (78.5) |
12 (70.6) |
61 (80.3) |
0.589 |
|
≥65 |
20 (21.5) |
5 (29.4) |
15 (19.7) |
|
|
OAD kullanımı, n(%) |
|
|
|
|
|
(-) |
75 (80.6) |
12 (70.6) |
63 (82.9) |
0.308 |
|
(+) |
18 (19.4) |
5 (29.4) |
13 (17.1) |
|
|
Basal examination |
|
|
|
|
|
OGTT 0.min (mg/dL) |
106.0±9.7 |
113.1±9.1 |
104.4±9.2 |
0.001* |
|
OGTT 120.min (mg/dL) |
148.0±31.3 |
166.2±41.2 |
143.8±27.4 |
0.007* |
|
HbA1c (%) |
5.8±1.0 |
6.1±0.6 |
5.7±1.1 |
0.320 |
|
Uric acid (mg/dL) |
5.1 (2.3-10.9) |
5.1 (3.8-7.2) |
5.1 (2.3-10.9) |
0.945 |
|
Total bilirubin (mg/dL) |
0.5 (0.1-1.4) |
0.5 (0.2-1.4) |
0.5 (0.1-1.3) |
0.822 |
|
Direct bilirubin (mg/dL) |
0.1 (0.1-1.4) |
0.1 (0.1-0.4) |
0.1 (0.1-1.4) |
0.978 |
|
II. visit examination |
|
|
|
|
|
FBG (mg/dL) |
112.8±28.0 |
146.6±45.5 |
105.2±14.2 |
0.002* |
|
Control FBG (mg/dL) |
109.0±13.1 |
121.0±20.8 |
107.7±11.6 |
0.050* |
|
PPG (mg/dL) |
133.7±42.8 |
180.5±53.0 |
126.2±36.8 |
0.016* |
|
HbA1c (%) |
6.0±0.5 |
6.8±0.7 |
5.8±0.4 |
0.006* |
|
Uric acid (mg/dL) |
5.2 (1.5-8.5) |
5.0 (3.2-8.4) |
5.2 (1.5-8.5) |
0.538 |
|
Total bilirubin (mg/dL) |
0.4 (0.1-1.4) |
0.4 (0.2-1.1) |
0.4 (0.1-1.4) |
0.940 |
|
Direct bilirubin (mg/dL) |
0.2 (0.1-1.1) |
0.1 (0.1-0.4) |
0.1 (0.1-1.1) |
0.876 |
Categorical variables were expressed as numbers and percentage, numerical variables were expressed as mean±standard deviation or median (min-max).
*p < 0.05 was considered statistically significant.
OAD: Oral Anti-diabetic Drug, OGTT: Oral Glucose Tolerance Test, FBG: Fasting Blood Glucose, PPG: Post Prandial Glucose, HbA1c: Glycosylated Hemoglobin